Atlas Trials

Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma

Clinical trial NCT05627115 · NOT_YET_RECRUITING

Trial details

NCT number
NCT05627115
Sponsor
University College, London
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Hodgkin Lymphoma
Start date
2024-03-01
Primary completion
2028-10-01
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.